STOCK TITAN

Medicinova (MNOV) Stock Price, News & Analysis

MNOV NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
29 252 sessions, November 19, 2025 to November 19, 2026
Largest daily move
+36.9% close of September 17, 2026
1-year change
-11.2% closing prices, November 19, 2025 to November 19, 2026
1-month change
-9.3% closing prices, October 19, 2026 to November 19, 2026

Company Description

MediciNova, Inc. (MNOV) is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapies for serious diseases with unmet medical needs. According to company disclosures, MediciNova concentrates on inflammatory, fibrotic, and neurodegenerative conditions and maintains a commercial focus on the United States market. The company’s pipeline is built around two main compounds, MN-166 (ibudilast) and MN-001 (tipelukast), which have multiple mechanisms of action and have been used in numerous clinical programs.

Core business and development focus

MediciNova describes itself as a biopharmaceutical company developing a broad late-stage pipeline of small molecule therapies. Its current strategy, as outlined in SEC and press release materials, is to focus development activities on MN-166 for neurological and other disorders and on MN-001 for fibrotic and metabolic disorders. The company emphasizes late-stage clinical development, with several programs in Phase 2 and Phase 3, and notes a strong track record of securing investigator-sponsored clinical trials funded through government grants.

Key pipeline assets

MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). Company communications state that MN-166 is in late-stage clinical development for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (MS), and degenerative cervical myelopathy (DCM). It is also in development for glioblastoma, Long COVID, chemotherapy-induced peripheral neuropathy (CIPN), substance use disorder, and has been evaluated in patients at risk for acute respiratory distress syndrome (ARDS). MediciNova identifies MN-166 as its lead asset and reports that it is in Phase 3 for ALS and DCM and Phase 3–ready for progressive MS.

For ALS, MediciNova highlights the COMBAT-ALS Phase 2b/3 trial, a randomized, double-blind, placebo-controlled study assessing efficacy, safety, and tolerability of MN-166 over a 12‑month double-blind period followed by a 6‑month open-label period. Company updates note that 234 patients were randomized at multiple sites in the United States and Canada and that enrollment was completed, with the primary endpoint defined as the Combined Assessment of Function and Survival (CAFS). Secondary endpoints include ALSFRS-R score progression, muscle strength, and quality of life assessments. MediciNova also reports an Expanded Access Program for ALS supported by a large NIH research grant and multiple active sites.

MN-166 has received Orphan Drug Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA) and Orphan Designation from the European Medicines Agency (EMA) for the ALS indication, according to company press releases. MediciNova further notes that MN-166 is being evaluated in Phase 2 trials in Long COVID and substance dependence and has been studied in other indications such as glioblastoma and CIPN.

MN-001 (tipelukast) is described as a novel, orally bioavailable small molecule compound with anti-inflammatory and anti-fibrotic activity in preclinical models. Company materials state that MN-001 is thought to act through several mechanisms, including leukotriene receptor antagonism, inhibition of phosphodiesterase (mainly types 3 and 4), and inhibition of 5‑lipoxygenase (5‑LO). MediciNova reports that MN-001 has been shown to down‑regulate expression of genes that promote fibrosis, such as LOXL2, Collagen Type 1 and TIMP‑1, and genes that promote inflammation, including CCR2 and MCP‑1. It also reports that MN-001 inhibits triglyceride synthesis in hepatocytes by inhibiting arachidonic acid uptake.

MN-001 is being evaluated in fibrotic and metabolic disorders, including non‑alcoholic fatty liver disease (NAFLD), hypertriglyceridemia, and type 2 diabetes (T2DM). Company announcements describe a Phase 2 clinical trial (MN‑001‑NATG‑202) in patients with hypertriglyceridemia and NAFLD due to T2DM, designed as a multi‑center, randomized, double‑blind, placebo‑controlled study. Co‑primary endpoints include changes in liver fat content and fasting serum triglycerides, with secondary endpoints related to safety, tolerability, and lipid profile changes.

Scientific rationale and mechanisms

MediciNova highlights mechanistic research supporting its development programs. For MN‑001, a peer‑reviewed publication in the Journal of Atherosclerosis and Thrombosis is cited, showing that MN‑002, the major metabolite of MN‑001, significantly enhanced cholesterol efflux in macrophages by upregulating transport proteins ABCA1 and ABCG1. Company commentary states that this provides mechanistic insight into how MN‑001 and MN‑002 may influence cholesterol and lipid metabolism and suggests a potential therapeutic strategy for atherosclerosis and related metabolic disorders.

For MN‑166, MediciNova emphasizes its role as a PDE4 inhibitor and modulator of inflammatory cytokines, linking this pharmacology to neuroinflammation and oxidative stress pathways implicated in ALS progression and other neurodegenerative conditions. Company descriptions of the COMBAT‑ALS trial and other studies underscore the intent to evaluate neuroprotective and functional outcomes in patients with serious neurological diseases.

Clinical development footprint

Across its programs, MediciNova reports numerous clinical trials involving MN‑166 and MN‑001. For MN‑166, these include Phase 3 development in ALS and DCM, Phase 3‑ready status for progressive MS, and Phase 2 trials in Long COVID, substance dependence, and CIPN. For MN‑001, MediciNova notes prior Phase 2 work in idiopathic pulmonary fibrosis (IPF) and ongoing Phase 2 evaluation in NAFLD and metabolic conditions. The company also references investigator‑initiated trials, such as the OXTOX study in chemotherapy‑induced peripheral neuropathy in metastatic colorectal cancer, conducted at multiple clinical sites.

MediciNova repeatedly states that it has a strong record of securing investigator-sponsored clinical trials funded through government grants, including support from the U.S. National Institutes of Health (NIH) and its National Institute of Neurological Disorders and Stroke (NINDS). This funding model is presented as an important component of its development approach.

Capital markets and listings

According to SEC filings and press releases, MediciNova’s common stock is listed on the Nasdaq under the symbol MNOV. Company news also states that MediciNova is listed on the Standard Market of the Tokyo Stock Exchange under code 4875. In an S‑1 registration statement, MediciNova describes a Standby Equity Purchase Agreement with YA II PN, Ltd., under which shares of common stock may be sold from time to time, indicating an ongoing use of capital markets to support its development programs.

Regulatory and corporate governance

MediciNova is incorporated in Delaware, as disclosed in SEC filings. The company files periodic reports and current reports with the U.S. Securities and Exchange Commission and holds annual meetings of stockholders where matters such as director elections, auditor ratification, and advisory votes on executive compensation are presented for shareholder approval. These filings provide information on governance practices and shareholder voting outcomes.

Position within pharmaceutical preparation manufacturing

Within the broader pharmaceutical preparation manufacturing sector, MediciNova positions itself as a clinical-stage developer of small molecule therapeutics, with a focus on late-stage programs in neurology, inflammation, fibrosis, and metabolic disease. Rather than manufacturing a broad range of commercial products, the company’s disclosures emphasize research, clinical development, and regulatory strategy centered on its two core compounds, MN‑166 and MN‑001.

Stock Performance

$1.27
-4.51%
-0.06
Last updated: at
-11.2%
Performance 1 year
$65.1M

Medicinova (MNOV) closed at $1.27 on November 19, 2026. Over the past 12 months, the price has lost 11.2%.

See what a $1,000 investment in MNOV would be worth today

Average down calculator for MNOV

MNOV Metrics & Rankings

Price returns through November 19, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Medicinova has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include clinical trial. View all MNOV news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
640,000
Shares Sold
1
Transactions
Most Recent Transaction
3D Investment Partners Pte. Ltd. (Insider) sold 640,000 shares held indirectly @ $2.70 on September 25, 2026

Insider selling at Medicinova over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Medicinova generated $410K in revenue in FY2025, operating income reached -$13.3M, and net income was -$12.0M. Diluted earnings per share stood at -$0.24. The company generated -$9.8M in operating cash flow. The current ratio was 8.16, measuring current assets divided by current liabilities.

$410K
Revenue (FY2025)
-$12.0M
Net Income (FY2025)
-$9.8M
Operating Cash Flow

Upcoming Events

YEAR
2026
2026 Clinical

COMBAT-ALS data readout

Phase 2b/3 COMBAT-ALS trial top-line results; randomized across US & Canada
YEAR
2027
2027 Clinical

SEANOBI-ALS follow-ups

Final follow-ups for NIH-funded SEANOBI‑ALS EAP (200 pts) projected to conclude; data analysis and presentations to follow.
MAR
2027
March 2027 Clinical

Last patient final visit

Last patient final visit for the entire COMBAT-ALS study expected March 2027, marking completion of blinded and open-label periods.
SEP
2042
September 2042 Corporate

Ibudilast patent expiration

U.S. patent (ibudilast + anti-PD-1 for glioblastoma) allowed; patent expected to expire no earlier than September 2042.

Medicinova has 4 upcoming scheduled events. The next event, "COMBAT-ALS data readout", is expected in 2026. Investors can track these dates to stay informed about potential catalysts that may affect the MNOV stock price.

Short Interest History

Last 12 Months

Short interest in Medicinova (MNOV) currently stands at 285.2 thousand shares, down 2.4% from the previous reporting period, representing 0.6% of the float. Since November 2025, short interest has decreased by 38.8%.

Days to Cover History

Last 12 Months

Days to cover for Medicinova (MNOV) currently stands at 5.4 days, up 142.9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 59.1%. Across the settlements charted above, it has ranged from 1.0 to 11.8 days.

MNOV Company Profile & Sector Positioning

Medicinova (MNOV) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing MNOV often look at related companies in the same sector, including Coya Therapeutics, Inc. (COYA), Gossamer Bio, Inc. (GOSS), Tiziana Life Sciences Ltd. (TLSA), OKYO Pharma Limited (OKYO), and Cognition Therapeutics, Inc. (CGTX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MNOV's relative position within its industry.

Frequently Asked Questions

The current stock price of Medicinova (MNOV) is $1.27 as of November 19, 2026.

The market cap of Medicinova (MNOV) is approximately $65.1M. Learn more about what market capitalization means .

The FY2025 revenue of Medicinova (MNOV) is $410K, from its most recent completed fiscal year.

The FY2025 net income of Medicinova (MNOV) is -$12.0M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Medicinova (MNOV) is -$0.24 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Medicinova (MNOV) is -$9.8M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Medicinova (MNOV), current assets divided by current liabilities, was 8.16 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Medicinova (MNOV) is -$13.3M for FY2025, its most recent completed fiscal year. Learn about operating income.

MediciNova, Inc. is a clinical-stage biopharmaceutical company developing novel small molecule therapies for serious diseases with unmet medical needs. Company materials state that it focuses on inflammatory, fibrotic, and neurodegenerative diseases and builds its pipeline around two core compounds, MN-166 (ibudilast) and MN-001 (tipelukast).

MediciNova highlights two main drug candidates: MN-166 (ibudilast) and MN-001 (tipelukast). MN-166 is a small molecule that inhibits PDE4 and inflammatory cytokines and is in late-stage development for neurodegenerative diseases such as ALS, progressive MS, and DCM, as well as other indications. MN-001 is an orally bioavailable small molecule with anti-inflammatory and anti-fibrotic activity being studied in fibrotic and metabolic disorders including NAFLD and hypertriglyceridemia.

According to MediciNova, MN-166 (ibudilast) is in late-stage clinical development for amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (MS), and degenerative cervical myelopathy (DCM). It is also in development for glioblastoma, Long COVID, chemotherapy-induced peripheral neuropathy (CIPN), and substance use disorder, and has been evaluated in patients at risk for acute respiratory distress syndrome (ARDS).

The COMBAT-ALS trial is MediciNova’s Phase 2b/3 randomized, double-blind, placebo-controlled study evaluating MN-166 (ibudilast) in patients with amyotrophic lateral sclerosis (ALS). Company announcements state that 234 patients were randomized across multiple sites in the United States and Canada, with a 12‑month treatment period followed by a 6‑month open-label period. The primary endpoint is the Combined Assessment of Function and Survival (CAFS), with secondary endpoints including ALSFRS-R score progression, muscle strength, and quality of life.

MediciNova reports that MN-001 (tipelukast) exerts anti-inflammatory and anti-fibrotic activity through several mechanisms in preclinical models. These include leukotriene receptor antagonism, inhibition of phosphodiesterase (mainly types 3 and 4), and inhibition of 5‑lipoxygenase (5‑LO). The company also notes that MN-001 down‑regulates genes associated with fibrosis and inflammation and inhibits triglyceride synthesis in hepatocytes by reducing arachidonic acid uptake.

Company disclosures state that MN-001 (tipelukast) has been evaluated in Phase 2 trials for idiopathic pulmonary fibrosis (IPF) and is being studied in non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia due to type 2 diabetes (T2DM). The MN‑001‑NATG‑202 Phase 2 trial is a randomized, double-blind, placebo-controlled study in patients with hypertriglyceridemia and NAFLD due to T2DM.

Yes. MediciNova reports that MN-166 (ibudilast) has received Orphan Drug Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of ALS, as well as Orphan Designation from the European Medicines Agency (EMA).

According to company press releases and SEC filings, MediciNova’s common stock is listed on the Nasdaq under the symbol MNOV. The company also states that its shares are listed on the Standard Market of the Tokyo Stock Exchange under code 4875.

MediciNova repeatedly notes that it has a strong track record of securing investigator-sponsored clinical trials funded through government grants. Examples cited by the company include collaborations with the U.S. National Institutes of Health and its National Institute of Neurological Disorders and Stroke, as well as other investigator-initiated studies.

In its SEC registration statement, MediciNova states that it is focused on developing novel therapeutics for serious diseases with unmet medical needs and that it has a commercial focus on the United States market. The company’s development strategy centers on advancing MN-166 and MN-001 through clinical trials in indications where it sees significant unmet need.